How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

998 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Androgen Excess as a Mechanism for Adipogenic Dysfunction in PCOS Women

Androgen Excess as a Mechanism for Adipogenic Dysfunction in PCOS Women Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Androgen Excess (...) for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 32 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women Study Start Date : April 2013 Estimated Primary Completion Date : June 30, 2022 Estimated Study Completion Date : June 30, 2022 Resource links provided

2013 Clinical Trials

182. Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2013 Clinical Trials

183. Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling

Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling Phase II Trial of Enzalutamide for CRPC With Correlative Assessment of Androgen Receptor Signaling - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Phase II Trial of Enzalutamide for CRPC With Correlative Assessment of Androgen Receptor Signaling The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01942837 Recruitment Status : Active, not recruiting First Posted : September 16, 2013

2013 Clinical Trials

184. Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies

Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail (...) Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

2013 Clinical Trials

185. GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01918306 Recruitment Status : Terminated (company stopped

2013 Clinical Trials

186. Androgenic alopecia

Androgenic alopecia Pattern hair loss - Wikipedia Pattern hair loss From Wikipedia, the free encyclopedia (Redirected from ) Pattern hair loss Other names Androgenic alopecia, androgenetic alopecia, male pattern baldness, female androgenic alopecia, female pattern baldness Male-pattern hair loss , Pattern hair loss , known as male-pattern hair loss ( MPHL ) when it affects males and female-pattern hair loss ( FPHL ) when it affects females, is that primarily affects the top and front (...) of 50 affects about half of males and a quarter of females. It is the most common cause of . Contents Signs and symptoms [ ] Classic male-pattern hair loss begins above the and vertex ( ) of the . As it progresses, a rim of hair at the sides and rear of the head remains. This has been referred to as a 'Hippocratic wreath', and rarely progresses to complete baldness. Pattern hair loss is classified as a form of non-scarring hair loss. The has been developed to grade androgenic alopecia in males

2012 Wikipedia

187. Androgen Replacement in Women

libido and sexual satisfaction Improves sense of well-being Appears to improve concentration and memory VII. Adverse Effects abnormalities (associated with oral androgens) tumors Cholestatic Iatrogenic Irreversible effects (Male patterned baldness) Voice deepening Clitoromegaly Reversible effects and oily skin (facial hair) Adverse effect on lipid profile Increases Decreases VIII. Causes: Secondary Causes of Hypoandrogenism Hypopituitarism Oophorectomy Secondary Medications lowering androgen levels (...) Androgen Replacement in Women Androgen Replacement in Women Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Androgen Replacement

2015 FP Notebook

188. Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer

when doubled. ] Known serum testosterone ≤ 150 ng/dl or symptoms of hypogonadism (fatigue, hot flashes, hair loss, loss of muscle mass, osteoporosis, low libido, depression) prior to ADT initiation not explained by other medical co-morbidity OR history of testosterone supplement. If questionable, serum testosterone level greater than 150 ng/dl can be used to exclude hypogonadism. Previous malignancy within 3 years other than non-melanomatous skin cancer and non-muscle invasive bladder cancer (...) Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2012 Clinical Trials

189. Androgen actions on the human hair follicle: perspectives. (Abstract)

Androgen actions on the human hair follicle: perspectives. Androgens stimulate beard growth but suppress hair growth in androgenetic alopecia (AGA). This condition is known as 'androgen paradox'. Human pilosebaceous units possess enough enzymes to form the active androgens testosterone and dihydrotestosterone. In hair follicles, 5α-reductase type 1 and 2, androgen receptors (AR) and AR coactivators can regulate androgen sensitivity of dermal papillae (DP). To regulate hair growth, androgens (...) stimulate production of IGF-1 as positive mediators from beard DP cells and of TGF-β1, TGF-β2, dickkopf1 and IL-6 as negative mediators from balding DP cells. In addition, androgens enhance inducible nitric oxide synthase from occipital DP cells and stem cell factor for positive regulation of hair growth in beard and negative regulation of balding DP cells. Moreover, AGA involves crosstalk between androgen and Wnt/β-catenin signalling. Finally, recent data on susceptibility genes have provided us

2012 Experimental Dermatology

190. Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. Full Text available with Trip Pro

hyperandrogenism and idiopathic hirsutism.A multicenter prevalence survey included 592 consecutive premenopausal women (393 from Madrid, Spain and 199 from Bologna, Italy) reporting spontaneously for blood donation. Immediately before donation, we conducted clinical and biochemical phenotyping for androgen excess disorders. We determined the prevalence of (i) hirsutism, acne and alopecia as clinical signs of androgen excess and (ii) functional disorders of androgen excess, including PCOS, defined (...) by the National Institute of Child Health and Human Development/National Institute of Health criteria, idiopathic hyperandrogenism and idiopathic hirsutism.Regarding clinical signs of hyperandrogenism, hirsutism and acne were equally frequent [12.2% prevalence; 95% confidence interval (CI): 9.5-14.8%], whereas alopecia was uncommon (1.7% prevalence, 95% CI: 0.7-2.7%). Regarding functional disorders of androgen excess, PCOS and idiopathic hirsutism were equally frequent (5.4% prevalence, 95% CI: 3.6-7.2

2012 Human Reproduction

191. Effects of topical application of EGCG on testosterone-induced hair loss in a mouse model. (Abstract)

 < 0.05). Topical EGCG down-regulated the T-induced expression of androgen receptor but did not down-regulate 17β-hydroxysteroid dehydrogenase (HSD) and three β-HSD expression. Analysis using liquid chromatography tandem mass spectrometry (LC-MS/MS) on serum and tissue samples revealed no significant difference in T and dihydrotestosterone concentrations between the T-injected and T + EGCG groups. Thus, we found that T injection in a mouse model induces hair loss by apoptosis of the hair follicles (...) Effects of topical application of EGCG on testosterone-induced hair loss in a mouse model. We investigated the effect of topical epigallocatechin-3-gallate (EGCG) on testosterone (T)-induced hair loss in mice. Marked hair loss was observed at the T-injected site, and topical EGCG significantly reduced the hair loss (P < 0.05). TUNEL staining showed apoptosis of follicular epithelial cells in the T-injected groups where topical EGCG was found to significantly diminish T-induced apoptosis (P

2011 Experimental Dermatology

192. Alopecia

variant of lichen planopilaris. Etiology The alopecias comprise a large group of disorders with multiple and varying etiologies ( ). The most common cause of alopecia is Androgenetic alopecia (male-pattern or female-pattern hair loss) Androgenetic alopecia is an androgen-dependent hereditary disorder in which dihydrotestosterone plays a major role. This form of alopecia may eventually affect up to 80% of white men by the age of 70 (male-pattern hair loss) and about half of all women (female-pattern (...) number of broken hairs. Primary hair shaft abnormalities are usually obvious on microscopic examination of the hair shaft. Scalp biopsy is indicated when alopecia persists and diagnosis is in doubt. Biopsy may differentiate scarring from nonscarring forms. Specimens should be taken from areas of active inflammation, ideally at the border of a bald patch. Fungal and bacterial cultures may be useful. Daily hair counts can be done by the patient to quantify hair loss when the pull test is negative

2013 Merck Manual (19th Edition)

193. Androgenetic Alopecia in Fabry Disease

is to assess whether patients with the classic form of Fabry disease have significantly less androgenic alopecia (male pattern baldness). Condition or disease Fabry Disease Detailed Description: Objectives: To test the hypothesis that adult males with classic form of Fabry disease have a significantly lower incidence of androgenic alopecia than matched controls. Study Population: 120 patients aged 20-64 with Fabry disease that have GLA mutations or alpha-galactosidase A activity associated with no residual (...) enzyme activity and non-Fabry male controls of the same age range and the same number of non-Fabry controls. Design: This is a cross-sectional study comparing the prevalence of androgenic alopecia in two groups of subjects. Outcome Measures: The levels of the outcome will be no androgenic alopecia and frontal only androgenetic alopecia opposed to vertex only and frontal and vertex androgenetic alopecia. Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment

2011 Clinical Trials

194. Androgenetic alopecia as an early marker of benign prostatic hyperplasia. (Abstract)

Androgenetic alopecia as an early marker of benign prostatic hyperplasia. Androgenetic alopecia (AGA) and benign prostatic hyperplasia are both androgen-dependent entities that respond to the blocking of 5-alpha-reductase.The objective of this study was to determine whether prostatic volumes and urinary flow changes were higher in patients with early-onset AGA than in healthy control subjects.This was an observational case-control study of 87 men: 45 with early-onset AGA diagnosed

2011 Journal of American Academy of Dermatology

195. Brain-derived nerve factor and neurotrophins in androgenetic alopecia. (Abstract)

Brain-derived nerve factor and neurotrophins in androgenetic alopecia. Several growth factors and cytokines have been shown to be involved in normal hair cycling as well as in androgenetic alopecia (AGA). However, the molecular cascades in AGA downstream from androgen receptor activation are far from being fully elucidated.We sought to determine the difference in the protein expression of growth factors/cytokines in balding vs. nonbalding scalp specimens from the same individuals affected (...) (P < 0·001). Expression of neurotrophin-3 and of β-nerve growth factor was also upregulated. On the other hand, protein expression of insulin-like growth factor-1 and its binding proteins as well as of the vascular endothelial growth factor family were significantly downregulated in the balding scalp.Neurotrophic factors, especially BDNF, may be important in mediating the effects of androgens on hair follicles, serving as a negative regulatory control signal. Further studies may lead to novel

2011 British Journal of Dermatology

196. Female Pattern Hair Loss in Complete Androgen Insensitivity Syndrome. (Abstract)

Female Pattern Hair Loss in Complete Androgen Insensitivity Syndrome. Female pattern hair loss, also known as female androgenetic alopecia, is generally regarded as an androgen-dependent disorder representing the female counterpart of male balding. We describe female pattern hair loss occurring in a patient with complete androgen insensitivity syndrome suggesting that mechanisms other than direct androgen action contribute to this common form of hair loss in women.

2010 British Journal of Dermatology

197. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. Full Text available with Trip Pro

The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. BACKGROUND: Cachexia, also known as muscle wasting, is a complex metabolic condition characterized by loss of skeletal muscle and a decline in physical function. Muscle wasting is associated with cancer, sarcopenia, chronic obstructive pulmonary disease, end-stage renal disease (...) , and other chronic conditions and results in significant morbidity and mortality. GTx-024 (enobosarm) is a nonsteroidal selective androgen receptor modulator (SARM) that has tissue-selective anabolic effects in muscle and bone, while sparing other androgenic tissue related to hair growth in women and prostate effects in men. GTx-024 has demonstrated promising pharmacologic effects in preclinical studies and favorable safety and pharmacokinetic profiles in phase I investigation. METHODS: A 12-week double

2011 Journal of cachexia, sarcopenia and muscle Controlled trial quality: predicted high

198. Androgenic hair

Androgenic hair Body hair - Wikipedia Body hair From Wikipedia, the free encyclopedia (Redirected from ) Body hair Hair on the Distribution of body hair in women and men [ ] Body hair , or androgenic hair , is the that develops on the during and after . It is differentiated from the and less visible , which are much finer and lighter in color. The growth of androgenic hair is related to the level of (often referred to as male ) and the density of androgen receptors in the dermal papillae. Both (...) hair, such as the first growth of on a male and female 's previously smooth chin; although it may appear thinner on the female. Androgenic hair follows the same as the hair that grows on the scalp, but with a shorter and longer . While the anagen phase for the hair on one's head lasts for years, the androgenic hair growth phase for body hair lasts a few months. The telogen phase for body hair lasts close to a year. [ ] This shortened growing period and extended dormant period explains why the hair

2012 Wikipedia

199. Partial androgen insensitivity syndrome

is indicated when secondary terminal hair is present, whereas grade 7 is indicated when it is absent. The can be used in conjunction with the traditional three classes of AIS to provide additional information regarding the degree of genital masculinization, and is particularly useful when the diagnosis is PAIS. Left , 19-year-old man with grade 3 PAIS before initiation of androgen therapy. Right , Habitus after 3.5 years of androgen treatment. Partial androgen insensitivity syndrome is diagnosed when (...) Partial androgen insensitivity syndrome Partial androgen insensitivity syndrome - Wikipedia Partial androgen insensitivity syndrome From Wikipedia, the free encyclopedia Partial androgen insensitivity syndrome Other names Partial androgen resistance syndrome results when the function of the (AR) is impaired. The AR protein (pictured) mediates the effects of androgens in the human body. Partial androgen insensitivity syndrome ( PAIS ) is a condition that results in the partial inability

2012 Wikipedia

200. Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia

in women may identify the group that will respond. This study is designed to test the impact of finasteride therapy on hair loss in postmenopausal women. Condition or disease Intervention/treatment Phase Androgenetic Alopecia Drug: Finasteride Phase 1 Detailed Description: Androgen sensitivity in the cell is determined by the number of Cytosine-Adenine-Guanine repeats in the Androgen Receptor gene. Lower CAG repeats have been associated in previous studies with androgenic conditions such as acne (...) Posted : January 20, 2010 Last Update Posted : January 20, 2010 Sponsor: HairDx, LLC Information provided by: HairDx, LLC Study Details Study Description Go to Brief Summary: Previous studies of finasteride treatment in women with hair loss have failed to show positive results, yet, some women have responded anecdotally. Given that polymorphisms of the androgen receptor gene which confer androgen sensitivity impact male response to finasteride therapy, it was hypothesized that the same polymorphism

2010 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>